Northern Trust Corp Sells 19,304 Shares of Humana Inc. $HUM

Key Points

• Northern Trust Corp reduced its stake in Humana Inc. by 1.6%, selling 19,304 shares and maintaining ownership of approximately 1,196,891 shares, valued at $316.7 million.
• Humana reported $6.27 EPS for the last quarter, missing estimates, despite a 9.6% year-over-year revenue growth to $32.39 billion.
• Analysts have given Humana a consensus rating of "Hold", with price targets ranging from **$272** to **$310** based on recent evaluations.

Northern Trust Corp lessened its stake in Humana Inc. (NYSE:HUM - Free Report) by 1.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,196,891 shares of the insurance provider's stock after selling 19,304 shares during the period. Northern Trust Corp owned about 0.99% of Humana worth $316,697,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of HUM. Vanguard Group Inc. lifted its stake in shares of Humana by 8.9% in the 1st quarter. Vanguard Group Inc. now owns 13,972,872 shares of the insurance provider's stock valued at $3,697,222,000 after acquiring an additional 1,143,662 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Humana by 40,881.1% in the 1st quarter. GAMMA Investing LLC now owns 781,099 shares of the insurance provider's stock valued at $2,066,790,000 after acquiring an additional 779,193 shares during the last quarter. Southpoint Capital Advisors LP bought a new stake in shares of Humana in the 4th quarter valued at about $190,282,000. Nuveen LLC bought a new stake in shares of Humana in the 1st quarter valued at about $171,220,000. Finally, 8 Knots Management LLC bought a new stake in shares of Humana in the 4th quarter valued at about $145,258,000. Institutional investors own 92.38% of the company's stock.

Humana Stock Up 0.6%

Shares of HUM stock traded up $1.87 during midday trading on Tuesday, reaching $299.07. 1,010,519 shares of the stock were exchanged, compared to its average volume of 1,836,657. Humana Inc. has a 1 year low of $206.87 and a 1 year high of $382.72. The company's 50 day moving average is $250.98 and its two-hundred day moving average is $253.78. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.69. The firm has a market cap of $35.97 billion, a PE ratio of 22.95, a price-to-earnings-growth ratio of 1.75 and a beta of 0.44.

Humana (NYSE:HUM - Get Free Report) last posted its earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). Humana had a return on equity of 13.67% and a net margin of 1.28%.The firm had revenue of $32.39 billion for the quarter, compared to analysts' expectations of $31.85 billion. During the same quarter last year, the company posted $6.96 EPS. The firm's revenue was up 9.6% on a year-over-year basis. Humana has set its FY 2025 guidance at 17.000- EPS. On average, equities research analysts predict that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be given a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date of this dividend is Friday, September 26th. Humana's payout ratio is currently 27.17%.

Wall Street Analyst Weigh In

HUM has been the topic of several recent analyst reports. Royal Bank Of Canada raised their target price on Humana from $283.00 to $322.00 and gave the stock an "outperform" rating in a research note on Thursday, August 21st. Truist Financial decreased their target price on Humana from $280.00 to $260.00 and set a "hold" rating for the company in a report on Wednesday, July 16th. Wells Fargo & Company cut their price target on shares of Humana from $348.00 to $344.00 and set an "overweight" rating on the stock in a report on Thursday, August 14th. Cantor Fitzgerald restated a "neutral" rating and issued a $290.00 price objective on shares of Humana in a report on Thursday, May 1st. Finally, Barclays set a $275.00 target price on shares of Humana and gave the stock an "equal weight" rating in a research report on Thursday, July 31st. Seven research analysts have rated the stock with a Buy rating and sixteen have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $283.29.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.